Home › Asset managers › Dimensional › 2024-2025 › Against the board
Two kinds of vote are listed: a board-sponsored proposal Dimensional voted AGAINST or withheld on, and a shareholder proposal it voted FOR, with the board’s recommendation on it where the filings show one. A FOR vote on a proposal the board supported, or took no position on, is listed and labelled, but it is not a vote against the board. One row is one proposal at one meeting; “funds” is how many of the manager’s funds or accounts voted that way.
Everything Only shareholder proposals it backed
6,073 proposals. The board-sponsored half of this list keeps the 6,000 proposals with the most funds behind them; the rest are in the interactive database. Every shareholder proposal it backed is listed in full.
| Company | Meeting | Proposal | Category | On the ballot from | Board recommended | Dimensional voted | Funds |
|---|---|---|---|---|---|---|---|
| Braemar Plc | July 3, 2024 | Re-elect Joanne Lake as Director | Director Elections | Board | AGAINST | 6 | |
| Breville Group Limited | November 7, 2024 | Approve Grant of Rights to Jim Clayton | Compensation | Board | AGAINST | 6 | |
| Breville Group Limited | November 7, 2024 | Approve Potential Termination Benefits | Compensation | Board | AGAINST | 6 | |
| Breville Group Limited | November 7, 2024 | Approve Remuneration Report | Compensation | Board | AGAINST | 6 | |
| Breville Group Limited | November 7, 2024 | Elect Lawrence Myers as Director | Director Elections | Board | AGAINST | 6 | |
| C3.ai, Inc. | October 2, 2024 | Advisory vote to approve the compensation of our named executive officers. | Say-on-Pay | Board | AGAINST | 6 | |
| C3.ai, Inc. | October 2, 2024 | Election of Class I Directors: KR Sridhar | Director Elections | Board | WITHHOLD | 6 | |
| C3.ai, Inc. | October 2, 2024 | Election of Class I Directors: Thomas M. Siebel | Director Elections | Board | WITHHOLD | 6 | |
| CCS Supply Chain Management Co., Ltd. | January 8, 2025 | Approve Estimated Amount of External Guarantees | Capital Structure | Board | AGAINST | 6 | |
| CSE Global Limited | April 21, 2025 | Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights | Capital Structure | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Attribution of Profit and Loss During the Transition Period | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Audit Report, Pro Forma Review Report and Valuation Report in Relation to the Transaction | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Authorization of the Board and Its Authorized Persons to Handle All Related Matters | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Completeness and Compliance of Implementation of Legal Proceedings of the Transaction and Validity of the Submitted Legal Documents | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Confidentiality Measures and Confidentiality System Adopted for This Transaction | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Description of the Basis and Fairness and Reasonableness of the Pricing of the Transaction | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Distribution Arrangement of Undistributed Earnings | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Fluctuation of the Company's Stock Price Before the Release of Information on This Transaction | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Impact of Dilution of Current Returns on Major Financial Indicators, the Relevant Measures to be Taken and Commitment from Relevant Parties | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Independence of Appraiser, the Validity of Hypothesis, the Relevance of Valuation Method and Purpose and Approach as Well as the Fairness of Pricing | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Amount | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Amount and Number of Issues | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Manner and Target Subscribers | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Type, Par Value and Listing Location | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Lock-Up Period Arrangement | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Overall Plan | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Performance Commitment and Compensation Arrangement | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Pricing Reference Date and Issue Price | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Purchases and Sales of Assets in the Twelve Months Prior to the Transaction | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Report (Draft) and Summary on Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds and Related Party Transactions | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Report on the Usage of Previously Raised Funds | Capital Structure | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Resolution Validity Period | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Signing of Conditional Agreement to the Issuance of Shares and Acquisition by Cash as well as Performance Compensation Agreement | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Target Assets | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies With Article 18 and 21 of the Measures for the Continuous Supervision of ChiNext Listed Companies (Trial) and Article 8 of the Shenzhen Stock Exchange Listed Company Major Asset Restructuring Review Rules | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies With Article 4 of Guidelines for the Supervision of Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructuring | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies with Articles 11 and 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies with the Relevant Provisions of the Administrative Measures for the Registration of Securities Issuance of Listed Companies | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Constitute as Major Asset Restructuring and Does Not Constitute as Restructuring and Listing | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Parties | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Price and Payment Method | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Use of Proceeds | Capital Structure | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve the Company's Plan for Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds Complies with Relevant Laws and Regulations | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve the Relevant Entity of Transaction Does Not Exist in Article 12 of Listed Company Supervision Guidelines No. 7 and Article 30 of the Guidelines for Self-regulatory Supervision No. 8 (Revised in 2023) | Extraordinary Transactions | Board | AGAINST | 6 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | April 15, 2025 | Approve Use of Idle Raised Funds and Own Funds for Cash Management | Extraordinary Transactions | Board | AGAINST | 6 | |
| Canny Elevator Co., Ltd. | April 18, 2025 | Approve Use of Own Funds to Invest in Financial Products | Extraordinary Transactions | Board | AGAINST | 6 | |
| CareCloud, Inc. | January 27, 2025 | To amend our Certificate of Incorporation to increase the Company's authorized shares of Common Stock from thirty-five million shares to eighty-five million shares: | Capital Structure | Board | AGAINST | 6 | |
| Carrefour SA | May 28, 2025 | Approve Compensation of Alexandre Bompard, Chairman and CEO | Compensation | Board | AGAINST | 6 | |
| Carrefour SA | May 28, 2025 | Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 165 Million | Capital Structure | Board | AGAINST | 6 | |
| Carrefour SA | May 28, 2025 | Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 15 to 17 | Capital Structure | Board | AGAINST | 6 | |
| Carrefour SA | May 28, 2025 | Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 165 Million | Capital Structure | Board | AGAINST | 6 | |
| Carrefour SA | May 28, 2025 | Reelect Charles Edelstenne as Director | Director Elections | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Approve Implementation of the Remuneration Policy | Compensation | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Approve Remuneration Policy | Compensation | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Approve Remuneration of Non-Executive Directors | Compensation | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Place Authorised but Unissued Shares under Control of Directors | Capital Structure | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Re-elect Albert Nemukula as Director | Director Elections | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Re-elect Albert Nemukula as Member of the Audit and Risk Committee | Director Elections | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Re-elect Connie Molusi as Member of the Audit and Risk Committee | Director Elections | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Re-elect Jack Phalane as Chairman of the Audit and Risk Committee | Director Elections | Board | AGAINST | 6 | |
| Caxton & CTP Publishers & Printers Ltd. | December 3, 2024 | Re-elect Paul Jenkins as Director | Director Elections | Board | AGAINST | 6 | |
| Cettire Limited | November 14, 2024 | Elect Richard Dennis (Rick) as Director | Director Elections | Board | AGAINST | 6 | |
| ChangYuan Technology Group Ltd. | September 13, 2024 | Approve Credit Line Application and Provision of Guarantee | Capital Structure | Board | AGAINST | 6 | |
| Chengxin Lithium Group Co., Ltd. | April 11, 2025 | Approve Provision of Guarantee | Capital Structure | Board | AGAINST | 6 | |
| China CSSC Holdings Ltd. | February 18, 2025 | Approve Framework Agreement on Provision of Guarantee | Capital Structure | Board | AGAINST | 6 | |
| China Design Group Co., Ltd. | May 20, 2025 | Approve Shareholder Return Plan | Capital Structure | Board | AGAINST | 6 | |
| China Design Group Co., Ltd. | May 20, 2025 | Approve Use of Idle Own Funds to Invest in Financial Products | Extraordinary Transactions | Board | AGAINST | 6 | |
| China Greatwall Technology Group Co., Ltd. | September 20, 2024 | Approve Capital Reduction and Related Party Transactions | Extraordinary Transactions | Board | AGAINST | 6 | |
| China Hanking Holdings Limited | May 20, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Capital Structure | Board | AGAINST | 6 | |
| China Hanking Holdings Limited | May 20, 2025 | Authorize Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 6 | |
| China Maple Leaf Educational Systems Limited | February 21, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Capital Structure | Board | AGAINST | 6 | |
| China Maple Leaf Educational Systems Limited | February 21, 2025 | Authorize Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 6 | |
| China Merchants Energy Shipping Co., Ltd. | April 29, 2025 | Approve Authorization on Provision of Guarantee for Subsidiaries | Capital Structure | Board | AGAINST | 6 | |
| Chongqing Zongshen Power Machinery Co., Ltd. | April 21, 2025 | Approve Financial Assistance Provision | Capital Structure | Board | AGAINST | 6 | |
| Chongqing Zongshen Power Machinery Co., Ltd. | April 21, 2025 | Approve Provision of Guarantee | Capital Structure | Board | AGAINST | 6 | |
| Chongqing Zongshen Power Machinery Co., Ltd. | April 21, 2025 | Approve the Company's Financial Management Business | Extraordinary Transactions | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries in the Framework of an Equity Line, up to Aggregate Nominal Amount of EUR 1,068,100 | Capital Structure | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to 30 Percent of Issued Share Capital | Capital Structure | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Approve Remuneration Policy of CEO | Compensation | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above | Capital Structure | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Authorize Capital Increase in Connection Above Delegation | Extraordinary Transactions | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Authorize Capital Increase of Up to EUR 1,068,100 for Future Exchange Offers | Capital Structure | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Authorize Capital Increase of up to 20 Percent of Issued Capital for Contributions in Kind | Capital Structure | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 1,068,100 | Capital Structure | Board | AGAINST | 6 | |
| Clariane SE | May 14, 2025 | Delegate Powers to the Board to Decide on Merger-Absorption, Split or Partial Contribution of Assets | Extraordinary Transactions | Board | AGAINST | 6 | |
| Clarus Corporation | May 29, 2025 | To consider and vote on a proposal to amend and restate the Company's 2015 Stock Incentive Plan to, among other things, extend the term of such plan by 10 years and reserve 7,500,000 shares of the Company's common stock for issuance under such plan; and | Compensation | Board | AGAINST | 6 | |
| Compagnie de Saint-Gobain SA | June 5, 2025 | Reelect Benoit Bazin as Director | Director Elections | Board | AGAINST | 6 | |
| Corcept Therapeutics Incorporated | June 10, 2025 | Election of Directors: David L. Mahoney | Director Elections | Board | WITHHOLD | 6 | |
| Cosan SA | April 30, 2025 | Elect Directors | Director Elections | Board | AGAINST | 6 | |
| Cosan SA | April 30, 2025 | Elect Joao Ricardo Ducatti as Fiscal Council Member and Guilherme Jose de Vasconcelos Cerqueira as Alternate | Compensation | Board | ABSTAIN | 6 | |
| Cosan SA | April 30, 2025 | Elect Monica Pires da Silva as Fiscal Council Member and Moises Cunha Mouta as Alternate | Compensation | Board | ABSTAIN | 6 | |
| DMCI Holdings, Inc. | October 15, 2024 | Approve Amendment of the Articles of Incorporation to Reclassify 10 Million of the Unissued Preferred Shares as Class B Preferred Shares | Capital Structure | Board | AGAINST | 6 | |
| DMCI Holdings, Inc. | October 15, 2024 | Approve Issuance of 10 Million Class B Preferred Shares to Dacon Corporation | Capital Structure | Board | AGAINST | 6 | |
| DUG Technology Ltd. | November 19, 2024 | Approve the Issuance of Up to 10 Percent of the Company's Issued Capital | Capital Structure | Board | AGAINST | 6 | |
| Dalipal Holdings Limited | May 23, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Capital Structure | Board | AGAINST | 6 | |
| Dalipal Holdings Limited | May 23, 2025 | Authorize Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 6 | |
| Dassault Systemes SE | May 22, 2025 | Approve Compensation Report of Corporate Officers | Compensation | Board | AGAINST | 6 | |
| Dassault Systemes SE | May 22, 2025 | Approve Compensation of Bernard Charles, Chairman of the Board | Compensation | Board | AGAINST | 6 | |
| Dassault Systemes SE | May 22, 2025 | Approve Compensation of Pascal Daloz, CEO | Compensation | Board | AGAINST | 6 | |
| Dassault Systemes SE | May 22, 2025 | Approve Remuneration Policy of Corporate Officers | Compensation | Board | AGAINST | 6 |
← Previous Page 50 of 61 Next →
← Back to Dimensional 2024-2025 overview
Built November 1, 2026 from SEC Form N-PX filings.